First Tracks Biotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0.
EPS: As of FY2026 Q2, the actual value is USD -0.95.
EBIT: As of FY2026 Q2, the actual value is USD -34.94 M.
The provided reference indicates that First Tracks Biotherapeutics, Inc. issued a press release on August 12, 2026, detailing its financial results for the three and six months ended June 30, 2026. However, the actual financial and operational metrics, cash flow details, unique company-specific indicators, or any forward-looking outlook/guidance are not included within the text provided in this specific reference document.